Traws Pharma, Inc.
TRAW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001130598
No open-market purchases or sales by Traws Pharma, Inc. insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $5.19M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Traws Pharma, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 19 | 19 | 0 |
| Shares | 1.73M | 1.26M | −468.8K (−27.1%) |
| Value | $3.98M | $1.87M | −$2.11M (−53.1%) |
New holders (4)
Institutions that held Traws Pharma, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Securities, LLC | 17,169 | $25.4K | 0.00% |
| Two Sigma Investments, LP | 16,063 | $23.8K | 0.00% |
| Raymond James Financial Inc | 102 | $151 | 0.00% |
| Citigroup Inc | 60 | $89 | 0.00% |
Sold out (4)
Institutions that held Traws Pharma, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Perceptive Advisors LLC | 421,781 | $970.1K |
| Boothbay Fund Management, LLC | 33,305 | $76.6K |
| Millennium Management LLC | 10,071 | $23.2K |
| Cornerstone Planning Group LLC | 1 | $1 |